Temozolomide is the only first-line drug in the treatment of recurrent glioma, and the levels of DNA repair gene O6-methylguanine DNA methyltransferase (MGMT) indicated sensitivity to the drug [6]. Here, MGMT is linked to central nervous system cancer.